Nanjing King-Friend Subsidiary Secures FDA Interchangeability Approval for Adalimumab Drug
MT Newswires Live
Sep 29
Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Emerge Bioscience received approval from the U.S. Food and Drug Administration for a Prior Approval Supplement or an interchangeability approval for its adalimumab injection, according to a Tuesday after-hours filing with the Shanghai bourse.
The drug is indicated for pain relief from rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in patients 2 years and older, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, chronic plaque psoriasis, ulcerative colitis, hidradenitis suppurativa, and non-infectious uveitis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.